Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Minerals Ltd. is pleased to announce that its Ordinary Shares have been approved to trade on the OTCQB Venture Market in the United States of America and have commenced trading under the ticker ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Annual Information Form for the year ended December 31, 2024, which may be accessed on Vertex's SEDAR+ profile at www.sedarplus.ca. The forward-looking statements contained in this Press Release ...

If you’re on the fence about investing in Elastic N.V., Vertex or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. Read on ...